ERBB2 and breast carcinoma: Studies have shown that the aberrant expression of MTFP1 in HER2-positive breast cancer is closely related to aggressiveness, which may affect the therapeutic sensitivity of cancer cells by regulating metabolic reprogramming (Baek et al., 2023).